Answers are grounded in this paper and cite their sources.
Expert commentary highlights multifactorial drivers of disease progression in autosomal dominant polycystic kidney disease, suggesting integrated models improve tailored clinical management.
We thank Catania et al.¹ for their insightful response to our article.² We wholeheartedly agree with the points raised in the letter and would like to respond with the following. The study of the intrafamilial variability of Mendelian disorders, including autosomal dominant polycystic kidney disease (ADPKD), represents a clinical conundrum. We consider the factors influencing variability in disease progression as conglomerate lifetime traits (Figure 1). Therefore, to address the significant data-to-evidence gap, the emerging framework that influences the clinical course variability of patients with ADPKD should integrate genetic, phenotypic, and environmental factors, as Catania et al.¹ highlighted.
No takes yet. Share an insight, caveat, or question.
Elhassan et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: